// App-Quantinova.ai

1390 : The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Researchers

Presenter

  • Charlotte Pawlyn

Principal Investigators

  • Tom Menzies

  • Faith E. Davies

  • Ritika Rana

  • Jennifer Pinney

  • Gordon Cook

  • Walter Martin Gregory

  • Matthew W Jenner

  • John R Jones

  • Martin F. Kaiser

  • Roger G Owen

  • Gareth Morgan

  • Graham H Jackson

  • David Cairns

  • Mark T Drayson

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY

  • Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Department of Haematology, University Hospitals NHS Foundation Trust, Bristol, United Kingdom

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Department of haematological sciences, Newcastle University, Newcastle-Upon-Tyne, United Kingdom,

  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute renal failure

  • Renal insufficiency

  • Renal disease

  • Multiple Myeloma

Biomarkers

  • Creatinine

Drug/Treatment

  • Lenalidomide

  • carfilzomib Intravenous

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved